Gut microbiota characteristics of gastric cancer patients across distinct pathological stages and their associations with tumor and paratumor mucosal microbiota
The study describes associations between gut dysbiosis and tumor/paratumoral microbial profiles in gastric cancer patients, but the text provided is insufficient to extract verifiable numerical results or effect direction.
| Population | Gastric cancer patients across distinct pathological stages |
|---|---|
| Exposure | Gut, tumoral, and paratumoral microbiota characterization by sequencing (16S rRNA and/or metagenomics) |
| Comparator | Not clearly specified in the provided text (possibly healthy controls or early vs. advanced stages) |
| Outcome | Gut microbiota composition by pathological stage; Association between gut and tumor microbiota; Microbial diversity (alpha and beta) by stage |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Gut microbiota composition by pathological stage | not extractable from provided text | — | Very low | — | |
| Association between gut and tumor microbiota | not extractable from provided text | — | Very low | — | |
| Microbial diversity (alpha and beta) by stage | not extractable from provided text | — | Very low | — |
Context
Gastric cancer is the fifth most common malignancy worldwide and the fourth leading cause of cancer-related death. H. pylori is the only Group I carcinogen bacterium, yet fewer than 3% of infected individuals develop gastric cancer, suggesting other microbial components participate in carcinogenesis. The gut–stomach axis is an increasingly investigated target in high-throughput sequencing and metagenomics.
What the study showed
Full results were not provided; only introduction/background was supplied. No numerical data, effect direction, 95% CI, or effect sizes can be extracted from the received material. The background references enrichment of Fusobacterium, Peptostreptococcus, Streptococcus, and Porphyromonas in gastric tumor tissue, and reduction of Lactobacillus, based on previously cited studies, not on original results of this article.
How it was done
Study design, sample size, duration, and population characteristics are unavailable in the provided text. The received text corresponds to introduction/background only, not to original methods or results of the indexed study.
Effect magnitude
No effect size with 95% CI can be extracted from the provided material.
Risk of bias
Full text was not provided; only a repeated introduction was received. Without original methods, results, and discussion sections, no risk of bias assessment (RoB 2, ROBINS-I, or AMSTAR-2) is applicable. Critical appraisal is structurally compromised.
What this study does NOT prove
This study, even with its full text, does not prove causality between dysbiosis and gastric cancer. The material provided does not allow any inference about the article's original results.
In clinical practice
No clinical recommendation can be derived from this incomplete material. Clinicians should await access to the full text with original results, methods, and discussion before any practical application.
Limitations
Full text was not provided; only a repeated introduction was received. Without original methods, results, and discussion sections, no risk of bias assessment (RoB 2, ROBINS-I, or AMSTAR-2) is applicable. Critical appraisal is structurally compromised.
What is still missing
Longitudinal prospective studies with adequate control groups are needed to establish causality between gut/tumoral microbial profiles and gastric cancer progression.
Technical appendix
Version history
- 1.0 · 2026-11-14 — Auto-generated under Evidence Standard v1.0
